Key Takeaways for Cleveland Practice Owners
- Northeast Ohio remains active in 2026, with national, regional, and PE-backed DSO buyers competing for $1.5M+ Cleveland practices.
- Valuations often hinge on normalized EBITDA, hygiene revenue above 30%, and associate-led production, with multiples typically ranging from 5x–11x depending on practice scale.
- Clinical autonomy and rebrand policies vary sharply by buyer category, so clear expectations before exclusivity can help protect seller interests.
- Offers commonly include a mix of cash at close, rollover equity, and earnouts, which usually require careful review and negotiation.
- McLerran & Associates runs a competitive sell-side process that can support stronger valuations and more favorable structures, so schedule a free, confidential discovery call to explore your options.
Current DSO Activity Around Cleveland and Northeast Ohio
DSO consolidation activity in Ohio has continued through 2025 and 2026. Multiple groups have completed Ohio acquisitions in the first half of 2026, including some entering the state for the first time and others expanding their presence in Northeast Ohio. A Cleveland-area group expanded its network throughout Northeast Ohio, which shows that both regional density strategies and national platforms are active in the market.
DSO acquisition demand remains active while the supply of premium dental practices is limited, which can create conditions that may favor prepared owners. The American Dental Association places U.S. dentistry at 16.1% DSO-affiliated under its narrow definition as of 2024, so the majority of practices remain independent and various buyer categories continue to seek quality practices.
For a $1.5M+ Cleveland practice, relevant buyer categories often include large national platforms with Midwest presence, regional groups building density in Ohio, and private-equity-backed organizations seeking add-on opportunities. McLerran & Associates’ Cleveland office, led by Justin Klingshim, maintains relationships across these categories and has completed transactions in Ohio.
How DSOs Value $1.5M+ Northeast Ohio Practices
Most DSO buyers focus on normalized, adjusted EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. EBITDA represents the practice’s cash-generating ability after adjusting for owner personal expenses and non-recurring costs. The multiple applied to this figure, and therefore the total enterprise value, can vary based on several factors.
DSOs typically pay 5x–8x EBITDA for single-location practices and add-on acquisitions, and 8x–11x for multi-location platforms with $1M+ EBITDA. The highest multiples, reaching 9x–11x (up to 12x+) for multi-location regional groups or platform deals with $5M+ in adjusted EBITDA, tend to be associated with multi-location or platform-grade assets. These are ranges rather than guarantees, and each outcome depends on the practice’s profile and the level of buyer competition.
Hygiene revenue and associate production can be some of the main factors that influence value. Hygiene revenue above 30% of collections and associate-led production, where the owner accounts for less than 70% of chair time, can provide a meaningful multiple lift and help reduce valuation discounts tied to owner dependence. A diligence-grade EBITDA analysis, prepared by McLerran’s CPA-led team before the practice goes to market, helps establish the story around these adjustments so the number is more likely to hold when buyers review it.
Clinical Autonomy and Rebrand Policies in Real-World Deals
Clinical autonomy often becomes one of the most negotiated and most misunderstood terms in a DSO affiliation. DSO-affiliated structures generally leave the dentist with clinical autonomy on paper while the DSO controls business operations through a long-term management services agreement, so sellers should expect limits around staffing, service offerings, hours, insurance contracts, fees, and marketing.
Rebrand policies can differ sharply by buyer category. Some national platforms require full adoption of a standardized consumer brand. Others maintain multiple regional brand identities and allow acquired practices to retain local identity while consolidating back-office services. Some buyers also allow the selling doctor to retain a meaningful ownership stake in their specific practice after the acquisition, which can preserve local brand identity alongside cash and equity rollover.
Misalignment between sellers and DSO buyers on clinical autonomy can negatively affect transition quality, employment negotiations, rollover equity appetite, and the seller’s willingness to remain involved after closing. Clear expectations around autonomy and branding before exclusivity, while multiple buyers remain at the table, form a core part of McLerran’s sell-side process.
Cash at Close, Rollover Equity, and Earnouts
Every DSO offer usually contains three components: cash at close, rollover equity, and an earnout. A seller who understands each piece before signing a letter of intent (LOI) can often negotiate from a stronger position.
Cash at close is the portion paid immediately upon closing. Many DSOs are offering deals where a majority of total consideration is paid as cash at close, although the achievable percentage depends on the practice’s profile, payer mix, and the buyer’s capital structure.
Rollover equity is ownership in the DSO, effectively stock in the acquiring company, that the seller receives instead of cash. Equity can represent 15%–30% of total deal value and can be held at the joint-venture level, with ongoing distributions and a higher floor but lower ceiling, or at the holding-company level, with no distributions but a higher ceiling if the platform recapitalizes at a higher multiple. Roughly 78% of surveyed DSOs anticipate recapitalization within 12 to 36 months, which can create meaningful upside or meaningful risk for equity holders.
Earnouts are contingent payments tied to hitting financial targets 1–3 years post-close. Many DSO acquisitions include earnout or equity rollover structures where 20%–40% of the purchase price is deferred, with earnouts, typically 5%–30%, subject to clawbacks if post-sale targets are missed. McLerran negotiates for non-punitive earnout terms, such as pro-rata provisions and later start dates, to help protect sellers from targets they can no longer control.
Why a Competitive Sale Process Can Help Sellers
Corporate development teams at DSOs negotiate dental practice acquisitions regularly, while a dental practice owner typically sells only once, which can create information asymmetry that disadvantages sellers from the first conversation. Accepting an unsolicited offer from a single DSO removes competitive tension, and that tension can be one of the main factors that influences price and terms.
Dental practice sellers entering the market in 2026 continue to receive offers, with final transaction values averaging 50% above initial offers due to competitive buyer dynamics. McLerran’s structured auction process typically generates around 10 offers within 45–60 days, and the firm’s clients transact at a higher rate than the broader market.
A competitive process with an experienced advisor can add value compared with a reactive sale to a single buyer. McLerran clients often see higher valuations and more balanced structures than owners who negotiate alone.
Understanding Buyer Categories in Today’s Market
The four primary DSO buyer categories active in Northeast Ohio differ in deal structure, equity risk, and pace of acquisitions. The comparison below highlights how cash-at-close profiles, equity exposure, and activity levels vary by buyer type, which can help you match a category to your goals.
| Buyer Category | Ohio Activity | Cash-at-Close Profile | Equity Risk |
|---|---|---|---|
| Large National Roll-Up (100+ affiliations/year) | Active across Ohio, Midwest concentration, completing 100+ affiliations annually | Significant cash at close common | Holding-company equity, risk tied to platform scale and PE sponsor strength |
| Regional Platform (10–50 affiliations/year) | Building Ohio density, 10–50 affiliations/year, Midwest-focused | Meaningful cash at close with 15%–30% rollover equity | JV or holding-company equity, moderate risk, distributions possible at JV level |
| PE-Backed Emerging Platform (add-on or platform acquisition) | Active in Ohio, entering new markets or building density around existing locations | Cash-at-close levels for add-ons vary, platform deals often more customized | Higher equity component possible, higher ceiling if platform recapitalizes, higher risk if undercapitalized |
| Family Office / Lower-Middle-Market Sponsor | Competing for platform and add-on deals in Ohio alongside institutional sponsors | Structure varies, often more flexible on mix of cash and equity | Lower liquidity, longer hold periods, equity value highly dependent on exit strategy |
Buyer Behaviors That May Signal Concerns
Some buyer behaviors can signal a higher-risk partner, especially when several appear together. These patterns often reflect a buyer trying to control information and limit your alternatives.
- Re-trading the deal after LOI. A buyer who reduces the agreed price during due diligence without a legitimate new finding uses exclusivity as leverage. McLerran’s quality-of-earnings defense and reminder that other vetted bidders are waiting can help counter this tactic.
- Punitive earnout structures. Earnouts tied to EBITDA targets the seller cannot influence after closing, because the DSO controls scheduling, marketing, and staffing, are a common source of post-close disputes. These structures often appear alongside aggressive re-trading.
- Undercapitalization. Provider risk, declining financial performance, and reimbursement exposure are among the top reasons DSOs walk away from deals, and the reverse also holds: a DSO with weak financials or an inexperienced PE sponsor can put the seller’s rollover equity at risk.
- Pressure to skip the competitive process. A buyer who insists on early exclusivity removes the competitive tension that helps protect the seller’s price and terms. This pressure often appears alongside re-trading and aggressive earnouts.
- Vague autonomy language. Sellers benefit from clear clinical autonomy expectations before exclusivity, while they still have alternatives. Ambiguous contract language on staffing, scheduling, and treatment planning is a red flag, especially when combined with the other behaviors above.
Schedule a free, confidential discovery call with McLerran & Associates to learn which buyers have been evaluated for Northeast Ohio practices and which ones may present concerns.
How McLerran’s Cleveland Office Guides the Sale Process
McLerran & Associates is a dental-only, sell-side advisory firm that represents the practice owner, not the buyer. Justin Klingshim leads the Cleveland office with direct knowledge of the Northeast Ohio market and recent Ohio closings. The firm’s process follows four stages.
- Understand your options. A CPA-led EBITDA analysis and comprehensive practice valuation, completed before the practice goes to market, establishes the true profitability of the practice and quantifies its worth in both the private-buyer and DSO markets side by side.
- Create competition. McLerran builds a marketing deck and virtual data room, then runs a structured, auction-like bid process among a vetted pool of national, regional, and PE-backed buyers, which typically generates around 10 offers within 45–60 days.
- Find the right fit. The process narrows to the top one to three finalists through in-person meetings and headquarters visits. McLerran produces multi-year, multi-structure financial forecasting so the owner can compare real after-tax proceeds across deal structures, not just headline numbers.
- Maximize your outcome. McLerran negotiates the LOI, defends the EBITDA through due diligence, and manages the transaction to close, with attention to the agreed value and the owner’s legacy, staff, and patients.
Across these stages, the goal is to improve both economics and fit compared with a one-off negotiation with a single buyer.
Frequently Asked Questions
Which buyer categories are actively closing in Cleveland right now?
All three major DSO buyer categories are active in Northeast Ohio in 2026: large national roll-ups with Midwest concentration, regional platforms building local density, and private-equity-backed emerging groups seeking add-on acquisitions. A Cleveland-area PE-backed group recently expanded its affiliated network throughout Northeast Ohio, and multiple national buyers entered Ohio for the first time in early 2026. For a $1.5M+ practice, the relevant buyer pool is often broader than most owners expect, which is why a competitive, sell-side process that surfaces multiple bidders can support stronger outcomes than responding to a single unsolicited offer.
How much cash at close can I realistically expect?
For a $1.5M+ revenue practice affiliating with a DSO, many deals fall within a range where a majority of total value is paid as cash at close, with the remainder structured as rollover equity and an earnout. The achievable percentage depends on adjusted EBITDA, payer mix, owner dependence, hygiene revenue as a share of collections, and the competitive tension created by having multiple buyers bidding at the same time. A practice with strong hygiene revenue, associate-led production, and a commercial PPO or fee-for-service payer mix tends to attract stronger cash-at-close offers. A diligence-grade EBITDA analysis and a competitive process, rather than a single buyer’s opening offer, provide the clearest picture of what is realistic for your practice.
Will I keep my brand and clinical autonomy?
Brand and autonomy outcomes depend heavily on which buyer you choose, and that choice becomes meaningful only when multiple buyers compete for your practice. Some national platforms require full rebranding to a standardized consumer brand. Others maintain regional brand identities and allow acquired practices to retain their local name. Some buyers allow the selling doctor to retain a meaningful ownership stake in their specific practice, which can preserve brand identity alongside cash and equity.
On clinical autonomy, DSO-affiliated structures generally leave the dentist with clinical decision-making authority on paper while the DSO controls business operations, although the degree of operational influence can vary significantly by buyer. Clear terms around autonomy and branding before exclusivity, with a sell-side advisor negotiating on your behalf, can help protect what matters most to you after the deal closes.
What happens if the DSO underperforms after I roll equity?
Rollover equity, the portion of your deal paid in DSO stock rather than cash, is illiquid and carries real performance risk. If the DSO underperforms, struggles financially, or fails to achieve a recapitalization at a higher multiple, the value of that equity can be significantly reduced. Many DSOs expect a recapitalization within 12–36 months, so platform quality can matter a great deal.
McLerran helps owners evaluate a DSO like an investment by reviewing the platform’s profitability, revenue growth at existing locations, management team experience, and the track record of the private equity sponsor backing it. A well-backed, well-run DSO with a clear path to recapitalization can present a very different risk profile than an undercapitalized group that emerged when capital flooded the space. The aim is to balance cash at close with equity exposure in a platform you feel comfortable owning.
The Case for a Competitive Process Before You Decide
A $1.5M+ Cleveland-area practice often represents a once-in-a-career financial event. DSOs negotiate deals every week. The information gap between a sophisticated DSO buyer and an unrepresented seller can show up directly in price, structure, and post-close terms. A competitive, sell-side process with a dental-only advisor gives you access to a larger premier buyer pool, more control over the EBITDA narrative, and the ability to compare cash-at-close levels and equity risk across multiple offers at the same time.
McLerran & Associates has completed approximately 2,000 successful practice sales, evaluated more than 10,000 practices, and closed roughly $2 billion in transaction volume, with a transaction rate that exceeds many general-market benchmarks. The firm is sell-side only, so its incentives align with the practice owner, not the buyer.
Schedule a free, confidential discovery call with McLerran & Associates. Justin Klingshim and the Cleveland team can walk you through your options, your valuation, and what a competitive process may look like for your practice.
Not ready to sell yet? Join the McLerran M&A Summit, October 29–30, 2026, a dental-only event built for owners who have not decided. Earn 4 CE credits, attend expert panels and one-on-one CPA sessions, and receive a complimentary practice valuation (a $2,500 value) so you can get educated before you commit to anything.
